I. Constitutional Gut Vulnerability

The gut system did not arrive at its current state through a single event. It was constitutionally shaped before any diagnosable disease appeared.

Continuous antibiotic exposure from infancy through age 7 for recurrent ear infections depleted the gut microbiome during the critical developmental window for mucosal immune maturation and autonomic nervous system development. The commensals that should have established during that period did not. The regulatory immune capacity, including mucosal tolerance, secretory IgA production, and T-regulatory cell development, that develops in the presence of a healthy early microbiome was impaired from the start. The chronic mastoiditis visible on brain imaging from 2016 through 2025 is structural evidence of the severity of the early infectious burden.

The consequences of this early disruption compounded over decades. Seropositive RA diagnosed in 2008, almost certainly active for years before diagnosis, maintained chronic systemic inflammation that subjected the mucosal barrier to sustained cytokine-driven stress throughout the subsequent decade. Microscopic colitis confirmed on biopsy in 2011 and 2015 documents active mucosal pathology during this period. The gut that helminthic therapy inherited in 2020 was already decades into a process of barrier dysfunction and immune dysregulation.

II. Intestinal Barrier Dysfunction: The Established Chronic Pattern

The intestinal barrier dysfunction in this patient is not a hypothesis. It is a documented, long-standing clinical pattern with multiple lines of supporting evidence.

The primary clinical signature is systemic inflammatory responses to food exposures, with joint swelling and muscle pain within hours of ingestion, rather than local gastrointestinal symptoms. This pattern is consistent with antigen translocation across a compromised mucosal barrier driving systemic immune activation. It is not classical food allergy. It is barrier-mediated systemic inflammation operating through a different mechanism entirely.

Persistently elevated IgA (359–531 mg/dL, consistently above the reference range of 87–352 mg/dL across multiple years) is consistent with chronic mucosal immune activation. Celiac serology has remained persistently positive, including elevated TTG IgA, elevated deamidated gliadin antibodies, and historically positive endomysial antibody, despite negative histology across multiple biopsies. The seronegative biopsy pattern does not exclude ongoing mucosal immune activation. It reflects the limitations of biopsy sampling rather than absence of pathology. The most recent duodenal biopsy, December 2025, showed no overt celiac disease but an increase in inflammatory cells in the mucosa, consistent with this same pattern of subclinical mucosal immune activity without a confirmatory histological diagnosis.

Confirmed mucosal diagnoses include collagenous colitis on biopsy in 2011 and 2015, and mild active microscopic colitis confirmed on the December 2025 colonoscopy. Microscopic colitis symptoms were absent from 2020 through early 2024. The histological abnormality persisted throughout. It was the symptoms that resolved with helminthic therapy, not the underlying condition.

Personal review of the December 2025 colonoscopy images shows a yellow-brown coating on the mucosal surface in the ascending colon and splenic flexure, visually distinct from the cleaner mucosal appearance elsewhere in the colon. This was not noted in the formal procedure report, which documented pathology findings rather than a visual description of mucosal surface appearance. This observation is the author’s own interpretation of the endoscopic images, not a documented endoscopic or pathologic finding, and a yellow-brown coating on imaging cannot be definitively distinguished from biofilm, retained luminal residue, or mucus without direct endoscopic assessment or special staining. It is noted here as a possible signal consistent with the broader gut picture, not as confirmed evidence of bacterial biofilm.

LPS Translocation and NF-κB Drive

The functional consequence of chronic barrier dysfunction is persistent low-level bacterial endotoxin (LPS) translocation into systemic circulation. LPS continuously stimulates TLR4 on macrophages. TLR4 activation feeds directly into NF-κB, driving transcription of TNF, IL-1β, IL-6, IL-18, and HMGB1 simultaneously. This mechanism operates independently of joint-specific RA pathology and provides a continuous systemic inflammatory drive that amplifies disease severity beyond what the underlying autoimmune process alone would produce.

This is not the cause of the RA. It is the engine that has been amplifying its severity and refractoriness throughout the clinical history, and it is the engine that the compromised vagal anti-inflammatory pathway can no longer adequately brake.

III. Hepcidin and Iron Absorption Dynamics

Hepcidin is a liver-derived peptide hormone that regulates systemic iron availability by blocking ferroportin, the primary cellular iron export channel. Under conditions of chronic inflammation, IL-6 and other cytokines drive sustained hepcidin upregulation through the STAT3 pathway. Elevated hepcidin traps iron in macrophages and intestinal enterocytes, blocking its release into circulation regardless of total body iron stores.

In a patient with decades of chronic autoimmune inflammatory activity, hepcidin upregulation is a persistent systemic feature, not a transient response to acute infection. The result is functional iron deficiency coexisting with adequate or elevated total body iron stores. Oral iron supplementation in this context faces active suppression of absorption at the enterocyte level. The gut cannot absorb what hepcidin will not release.

This dynamic has direct clinical implications for iron management that are independent of the gut barrier dysfunction and the dysbiosis picture, though both compound it. It explains the failure of standard oral iron approaches in this patient and contextualizes the decision to use intravenous iron, a decision that bypassed the absorption barrier entirely but with consequences documented in the Iron Dysbiosis reference.

The hepcidin-iron dynamic is not an intervention target in itself. It is a systemic feature of chronic autoimmune inflammatory load that must be understood when making any decisions about iron management in this patient.

IV. The Iron-Triggered Dysbiosis Event — Summary and Current Status

Two high-dose intravenous iron infusions, October 17, 2023 and February 22, 2024, were followed by a major shift in the gut microbiome: Thorne testing in August 2024 and again in September 2025 showed Proteobacteria and Enterobacteriaceae dominance at the 99.9th percentile, with commensal populations (Faecalibacterium, Roseburia, Akkermansia) collapsed relative to the October 2022 baseline. The persistence of this architecture across two draws a year apart, despite sustained dietary and probiotic intervention, supported a working hypothesis that the iron infusions had triggered a self-reinforcing, locked pathological state rather than a transient, recoverable disruption.

As of August 2026, that hypothesis is no longer corroborated as the current state. Two independent current-state platforms — Jona (June 2026) and Biomesight (August 2026, same platform as the October 2022 baseline, adequate sequencing depth) — both show Proteobacteria low and no Enterobacteriaceae dominance. This does not refute the 2024–2025 Thorne findings, which the 2026 tests cannot speak to retroactively, but it means the locked-attractor characterization should not be treated as the present microbiome state. The full mechanism, evidence, and current-status discussion are developed in the Iron Dysbiosis reference (III-c); this document defers to that one for detail rather than duplicating it.

V. The Gut-Vagus Connection

The gut and CNS systems are coupled bidirectionally through the vagus nerve. The mechanism — dysbiotic metabolites impairing vagal afferent signaling, and the resulting self-reinforcing coupling between a compromised gut and a compromised vagal anti-inflammatory brake — is documented in full in the Vagal Tone Deficit Mechanistic Reference (II-a), Section II.E, rather than restated here.

This coupling is why the CNS intervention, VNS, and the gut intervention, whatever clinical support pathway ultimately addresses the current gut picture, are not alternatives. They address different sides of the same coupled system, regardless of exactly how the current dysbiosis question resolves.

VI. Angioedema — Three Episodes, Early 2026

Three angioedema episodes occurred in early 2026, escalating in severity, the third involving laryngeal swelling and airway compromise. Hereditary angioedema and acquired C1 inhibitor deficiency have been formally excluded (C4, C1-INH functional and protein levels all normal or above normal, March 2026). Autoimmune urticaria has also been excluded (negative chronic urticaria panel, negative thyroid autoimmunity). Total IgE was markedly elevated (2849 IU/mL) with a near-negative specific-allergen panel — a pattern more consistent with polyclonal immune dysregulation than classic allergy, though this doesn’t point to a specific mechanism on its own. Two allergy/immunology specialists favor a non-bradykinin explanation; this is noted as their assessment, not adjudicated here. No further workup or daily antihistamine prophylaxis is currently planned. If further episodes occur, this warrants closer follow-up.